Nicolas Soldermann

Basel, BS 4002, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter.

Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter.

Journal: Journal of medicinal chemistry

Published: March 04, 2026

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Journal: Nature cancer

Published: June 17, 2024

Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Journal: Nature cancer

Published: May 22, 2023

Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.

Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.

Journal: ChemMedChem

Published: February 01, 2023

The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.

The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.

Journal: ChemMedChem

Published: June 01, 2022

Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.

Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.

Journal: Blood

Published: August 12, 2017

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Journal: ACS medicinal chemistry letters

Published: July 19, 2017

Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties.

Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties.

Journal: Bioorganic & medicinal chemistry letters

Published: September 05, 2016

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Journal: ACS medicinal chemistry letters

Published: March 17, 2016

Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.

Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.

Journal: Bioorganic & medicinal chemistry letters

Published: July 10, 2014

6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists.

6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists.

Journal: Bioorganic & medicinal chemistry letters

Published: October 21, 2011

Showing 1-11 of 11

Last Updated: 09/26/2026